<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35597820</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bone marrow-derived macrophages from a murine model of Sjögren's syndrome demonstrate an aberrant, inflammatory response to apoptotic cells.</ArticleTitle>
        <Pagination>
          <StartPage>8593</StartPage>
          <MedlinePgn>8593</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">8593</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-12608-4</ELocationID>
        <Abstract>
          <AbstractText>Sjögren's syndrome (SjS) is a female-dominated autoimmune disease involving lymphocytic infiltration of the exocrine glands. We have previously demonstrated cleavage of the TAM (Tyro3, Axl, Mer) receptor Mer is enhanced in SjS, leading to defective efferocytosis. Mer also plays a role in modulating phagocyte inflammatory response to apoptotic cells. Here we investigated the SjS macrophage response to apoptotic cells (AC). Bone marrow-derived macrophages (BMDMs) from SjS-susceptible (SjS<sup>s</sup>) C57BL/6.NOD-Aec1Aec2 mice and C57BL/6 (B6) controls were treated with either AC or CpG-oligodeoxynucleotides. RNA was collected from macrophages and bulk sequencing was performed to analyze transcripts. Cytokine expression was confirmed by Bio-plex. RT-qPCR was used to determine toll-like receptor (TLR) 7 and 9 involvement in BMDM inflammatory response to apoptotic cells. SjS<sup>S</sup> BMDMs exhibited a distinct transcriptional profile involving upregulation of a broad array of inflammatory genes that were not elevated in B6 BMDMs by AC. Inhibition of TLR 7 and 9 was found to limit the inflammatory response of SjS<sup>S</sup> BMDMs to ACs. ACs elicit an inflammatory reaction in SjS<sup>S</sup> BMDMs distinct from that observed in B6 BMDMs. This discovery of aberrant macrophage behavior in SjS in conjunction with previously described efferocytosis defects suggests an expanded role for macrophages in SjS, where uncleared dead cells stimulate an inflammatory response through macrophage TLRs recruiting lymphocytes, participating in co-stimulation and establishing an environment conducive to autoimmunity.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Witas</LastName>
            <ForeName>Richard</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, PO Box 110880, Gainesville, FL, 32611-0880, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Yiran</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, PO Box 110880, Gainesville, FL, 32611-0880, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nguyen</LastName>
            <ForeName>Cuong Q</ForeName>
            <Initials>CQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, PO Box 110880, Gainesville, FL, 32611-0880, USA. nguyenc@ufl.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, FL, USA. nguyenc@ufl.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Orphaned Autoimmune Diseases, University of Florida, Gainesville, FL, USA. nguyenc@ufl.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DE21990</GrantID>
            <Acronym>DE</Acronym>
            <Agency>NIDCR NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>23</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35597820</ArticleId>
        <ArticleId IdType="pmc">PMC9124194</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-022-12608-4</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-022-12608-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Helmick CG, et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15–25. doi: 10.1002/art.23177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.23177</ArticleId>
            <ArticleId IdType="pubmed">18163481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin B, et al.  Epidemiology of primary Sjögren's syndrome: A systematic review and meta-analysis. Ann. Rheum. Dis. 2015;74:1983–1989. doi: 10.1136/annrheumdis-2014-205375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2014-205375</ArticleId>
            <ArticleId IdType="pubmed">24938285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marketos N, Cinoku I, Rapti A, Mavragani CP. Type I interferon signature in Sjögren's syndrome: Pathophysiological and clinical implications. Clin. Exp. Rheumatol. 2019;37(Suppl 118):185–191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31376268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nezos A, et al.  Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. J. Autoimmun. 2015;63:47–58. doi: 10.1016/j.jaut.2015.07.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2015.07.002</ArticleId>
            <ArticleId IdType="pmc">PMC4564326</ArticleId>
            <ArticleId IdType="pubmed">26183766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soret P, et al.  A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome. Nat. Commun. 2021;12:3523. doi: 10.1038/s41467-021-23472-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-23472-7</ArticleId>
            <ArticleId IdType="pmc">PMC8192578</ArticleId>
            <ArticleId IdType="pubmed">34112769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szczerba BM, et al.  Type I interferon receptor deficiency prevents murine Sjogren's syndrome. J. Dent. Res. 2013;92:444–449. doi: 10.1177/0022034513483315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0022034513483315</ArticleId>
            <ArticleId IdType="pmc">PMC3627507</ArticleId>
            <ArticleId IdType="pubmed">23533183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cha S, et al.  A dual role for interferon-gamma in the pathogenesis of Sjogren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand. J. Immunol. 2004;60:552–565. doi: 10.1111/j.0300-9475.2004.01508.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.0300-9475.2004.01508.x</ArticleId>
            <ArticleId IdType="pubmed">15584966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lessard CJ, et al.  Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat. Genet. 2013;45:1284–1292. doi: 10.1038/ng.2792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.2792</ArticleId>
            <ArticleId IdType="pmc">PMC3867192</ArticleId>
            <ArticleId IdType="pubmed">24097067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witas R, Peck AB, Ambrus JL, Nguyen CQ. Sjogren's syndrome and TAM receptors: A possible contribution to disease onset. J. Immunol. Res. 2019;2019:4813795. doi: 10.1155/2019/4813795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/4813795</ArticleId>
            <ArticleId IdType="pmc">PMC6535826</ArticleId>
            <ArticleId IdType="pubmed">31214622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zagórska A, Través PG, Lew ED, Dransfield I, Lemke G. Diversification of TAM receptor tyrosine kinase function. Nat. Immunol. 2014;15:920–928. doi: 10.1038/ni.2986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2986</ArticleId>
            <ArticleId IdType="pmc">PMC4169336</ArticleId>
            <ArticleId IdType="pubmed">25194421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemke G. Biology of the TAM receptors. Cold Spring Harb. Perspect. Biol. 2013;5:a009076. doi: 10.1101/cshperspect.a009076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a009076</ArticleId>
            <ArticleId IdType="pmc">PMC3809585</ArticleId>
            <ArticleId IdType="pubmed">24186067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sather S, et al.  A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood. 2007;109:1026–1033. doi: 10.1182/blood-2006-05-021634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2006-05-021634</ArticleId>
            <ArticleId IdType="pmc">PMC1785151</ArticleId>
            <ArticleId IdType="pubmed">17047157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee YJ, et al.  Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice. Toxicol. Appl. Pharmacol. 2012;263:61–72. doi: 10.1016/j.taap.2012.05.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.taap.2012.05.024</ArticleId>
            <ArticleId IdType="pubmed">22687607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witas R, et al.  Defective efferocytosis in a Murine model of Sjögren's syndrome is mediated by dysfunctional mer tyrosine kinase receptor. Int. J. Mol. Sci. 2021;22:9711. doi: 10.3390/ijms22189711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22189711</ArticleId>
            <ArticleId IdType="pmc">PMC8466327</ArticleId>
            <ArticleId IdType="pubmed">34575873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawano M, Nagata S. Efferocytosis and autoimmune disease. Int. Immunol. 2018;30:551–558. doi: 10.1093/intimm/dxy055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/intimm/dxy055</ArticleId>
            <ArticleId IdType="pmc">PMC6234909</ArticleId>
            <ArticleId IdType="pubmed">30165442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weischenfeldt J, Porse B. Bone marrow-derived macrophages (BMM): Isolation and applications. CSH Protoc. 2008;2008:pdb.prot5080. doi: 10.1101/pdb.prot5080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/pdb.prot5080</ArticleId>
            <ArticleId IdType="pubmed">21356739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cifone MG, et al.  Dexamethasone-induced thymocyte apoptosis: apoptotic signal involves the sequential activation of phosphoinositide-specific phospholipase C, acidic sphingomyelinase, and caspases. Blood. 1999;93:2282–2296. doi: 10.1182/blood.V93.7.2282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V93.7.2282</ArticleId>
            <ArticleId IdType="pubmed">10090938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Migliorati G, Nicoletti I, Nocentini G, Pagliacci MC, Riccardi C. Dexamethasone and interleukins modulate apoptosis of murine thymocytes and peripheral T-lymphocytes. Pharmacol. Res. 1994;30:43–52. doi: 10.1016/1043-6618(94)80086-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/1043-6618(94)80086-3</ArticleId>
            <ArticleId IdType="pubmed">7831194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 2019;10:1523. doi: 10.1038/s41467-019-09234-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-09234-6</ArticleId>
            <ArticleId IdType="pmc">PMC6447622</ArticleId>
            <ArticleId IdType="pubmed">30944313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine background. Arthritis Rheum. 2002;46:1390–1398. doi: 10.1002/art.10258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.10258</ArticleId>
            <ArticleId IdType="pubmed">12115247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 2006;6:823–835. doi: 10.1038/nri1957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri1957</ArticleId>
            <ArticleId IdType="pmc">PMC7097510</ArticleId>
            <ArticleId IdType="pubmed">17063184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Killedar SJ, et al.  Early pathogenic events associated with Sjögren's syndrome (SjS)-like disease of the NOD mouse using microarray analysis. Lab. Investig. 2006;86:1243–1260. doi: 10.1038/labinvest.3700487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.3700487</ArticleId>
            <ArticleId IdType="pubmed">17075579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogelsang P, Karlsen M, Brun JG, Jonsson R, Appel S. Altered phenotype and Stat1 expression in Toll-like receptor 7/8 stimulated monocyte-derived dendritic cells from patients with primary Sjögren's syndrome. Arthritis Res. Ther. 2014;16:R166. doi: 10.1186/ar4682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar4682</ArticleId>
            <ArticleId IdType="pmc">PMC4261979</ArticleId>
            <ArticleId IdType="pubmed">25113744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karlsen M, et al.  Expression of toll-like receptors in peripheral blood mononuclear cells of patients with primary Sjögren's syndrome. Scand. J. Immunol. 2017;85:220–226. doi: 10.1111/sji.12520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/sji.12520</ArticleId>
            <ArticleId IdType="pubmed">27943374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiripolsky J, Kramer JM. Current and emerging evidence for toll-like receptor activation in Sjögren's syndrome. J. Immunol. Res. 2018;2018:1246818. doi: 10.1155/2018/1246818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2018/1246818</ArticleId>
            <ArticleId IdType="pmc">PMC6317121</ArticleId>
            <ArticleId IdType="pubmed">30671484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng L, Zhang Z, Yu C, Yang C. Expression of Toll-like receptors 7, 8, and 9 in primary Sjögren's syndrome. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010;109:844–850. doi: 10.1016/j.tripleo.2010.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tripleo.2010.01.006</ArticleId>
            <ArticleId IdType="pubmed">20399690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willeke P, et al.  Interleukin 1beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary Sjögren's syndrome. Ann. Rheum. Dis. 2003;62:359–362. doi: 10.1136/ard.62.4.359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.62.4.359</ArticleId>
            <ArticleId IdType="pmc">PMC1754485</ArticleId>
            <ArticleId IdType="pubmed">12634239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, et al.  TLR7 signaling drives the development of Sjögren's syndrome. Front. Immunol. 2021;12:676010. doi: 10.3389/fimmu.2021.676010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.676010</ArticleId>
            <ArticleId IdType="pmc">PMC8183380</ArticleId>
            <ArticleId IdType="pubmed">34108972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu T, et al.  Activation of Toll-like receptor 7 signaling in labial salivary glands of primary Sjögren's syndrome patients. Clin. Exp. Immunol. 2019;196:39–51. doi: 10.1111/cei.13242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.13242</ArticleId>
            <ArticleId IdType="pmc">PMC6422652</ArticleId>
            <ArticleId IdType="pubmed">30446998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maria NI, et al.  Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndrome. Ann. Rheum. Dis. 2017;76:721–730. doi: 10.1136/annrheumdis-2016-209589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2016-209589</ArticleId>
            <ArticleId IdType="pubmed">27672125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hillen MR, et al.  Plasmacytoid DCs from patients with Sjögren's syndrome are transcriptionally primed for enhanced pro-inflammatory cytokine production. Front. Immunol. 2019;10:2096. doi: 10.3389/fimmu.2019.02096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.02096</ArticleId>
            <ArticleId IdType="pmc">PMC6736989</ArticleId>
            <ArticleId IdType="pubmed">31552042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiripolsky J, McCabe LG, Gaile DP, Kramer JM. Myd88 is required for disease development in a primary Sjögren's syndrome mouse model. J. Leukoc. Biol. 2017;102:1411–1420. doi: 10.1189/jlb.3A0717-311R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.3A0717-311R</ArticleId>
            <ArticleId IdType="pmc">PMC6608061</ArticleId>
            <ArticleId IdType="pubmed">28951424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi H, et al.  Activation of TLR9-dependent p38MAPK pathway in the pathogenesis of primary Sjögren's syndrome in NOD/Ltj mouse. J. Oral Pathol. Med. 2014;43:785–791. doi: 10.1111/jop.12209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jop.12209</ArticleId>
            <ArticleId IdType="pubmed">25065264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphreys-Beher MG, Peck AB, Dang H, Talal N. The role of apoptosis in the initiation of the autoimmune response in Sjögren's syndrome. Clin. Exp. Immunol. 1999;116:383–387. doi: 10.1046/j.1365-2249.1999.00888.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2249.1999.00888.x</ArticleId>
            <ArticleId IdType="pmc">PMC1905316</ArticleId>
            <ArticleId IdType="pubmed">10361223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura H, et al.  Rapid and significant induction of TRAIL-mediated type II cells in apoptosis of primary salivary epithelial cells in primary Sjögren's syndrome. Apoptosis. 2008;13:1322–1330. doi: 10.1007/s10495-008-0261-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10495-008-0261-2</ArticleId>
            <ArticleId IdType="pubmed">18791828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong L, et al.  Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice. Clin. Exp. Rheumatol. 1998;16:675–681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9844759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong L, et al.  Bcl-2 family expression in salivary glands from patients with primary Sjögren's syndrome: Involvement of Bax in salivary gland destruction. Clin. Immunol. Immunopathol. 1998;88:133–141. doi: 10.1006/clin.1998.4556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/clin.1998.4556</ArticleId>
            <ArticleId IdType="pubmed">9714690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kramer JM. Early events in Sjögren's Syndrome pathogenesis: The importance of innate immunity in disease initiation. Cytokine. 2014;67:92–101. doi: 10.1016/j.cyto.2014.02.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2014.02.009</ArticleId>
            <ArticleId IdType="pubmed">24656928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ainola M, et al.  Activation of plasmacytoid dendritic cells by apoptotic particles—Mechanism for the loss of immunological tolerance in Sjögren's syndrome. Clin. Exp. Immunol. 2018;191:301–310. doi: 10.1111/cei.13077.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.13077</ArticleId>
            <ArticleId IdType="pmc">PMC5801512</ArticleId>
            <ArticleId IdType="pubmed">29105068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, Molinaro C, Johnson N, Casiano CA. Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity. Arthritis Rheum. 2001;44:2642–2652. doi: 10.1002/1529-0131(200111)44:11&lt;2642::aid-art444&gt;3.0.co;2-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1529-0131(200111)44:11&lt;2642::aid-art444&gt;3.0.co;2-8</ArticleId>
            <ArticleId IdType="pubmed">11710720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gamrekelashvili J, Greten TF, Korangy F. Immunogenicity of necrotic cell death. Cell Mol. Life Sci. 2015;72:273–283. doi: 10.1007/s00018-014-1741-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-014-1741-x</ArticleId>
            <ArticleId IdType="pmc">PMC6309818</ArticleId>
            <ArticleId IdType="pubmed">25274062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okuma A, et al.  Enhanced apoptosis by disruption of the STAT3-IκB-ζ signaling pathway in epithelial cells induces Sjögren's syndrome-like autoimmune disease. Immunity. 2013;38:450–460. doi: 10.1016/j.immuni.2012.11.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2012.11.016</ArticleId>
            <ArticleId IdType="pubmed">23453632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007;131:1124–1136. doi: 10.1016/j.cell.2007.10.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.10.034</ArticleId>
            <ArticleId IdType="pubmed">18083102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vartoukian SR, et al.  Dysregulation of the suppressor of cytokine signalling 3-signal transducer and activator of transcription-3 pathway in the aetiopathogenesis of Sjogren's syndrome. Clin. Exp. Immunol. 2014;177:618–629. doi: 10.1111/cei.12377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.12377</ArticleId>
            <ArticleId IdType="pmc">PMC4137846</ArticleId>
            <ArticleId IdType="pubmed">24827536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deshmukh US, et al.  Inflammatory stimuli accelerate Sjögren's syndrome-like disease in (NZB x NZW)F1 mice. Arthritis Rheum. 2008;58:1318–1323. doi: 10.1002/art.23368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.23368</ArticleId>
            <ArticleId IdType="pmc">PMC2721328</ArticleId>
            <ArticleId IdType="pubmed">18438852</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
